Nervous System Cancer

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Nervous System Cancer

MalaCards integrated aliases for Nervous System Cancer:

Name: Nervous System Cancer 12 15 17
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm 71
Malignant Neoplasm of Nervous System 12
Neoplasm of the Nervous System 29
Tumor of the Nervous System 12
Neoplasm of Nervous System 12
Nervous System Neoplasms 71
Nervous System Neoplasm 12
Neoplasms, Nerve Tissue 43
Nervous System--Cancer 71
Nervous System Tumor 54
Neural Neoplasm 12
Neural Tumor 12


External Ids:

Disease Ontology 12 DOID:3093
ICD9CM 34 192 192.9
MeSH 43 D009380
NCIt 49 C35562
UMLS 71 C0027665 C0027766 C0153643 more

Summaries for Nervous System Cancer

Disease Ontology : 12 An organ system cancer located in the nervous system that affects the central or peripheral nervous system.

MalaCards based summary : Nervous System Cancer, also known as neuroepithelial, perineurial, and schwann cell neoplasm, is related to central nervous system cancer and autonomic nervous system neoplasm. An important gene associated with Nervous System Cancer is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are MicroRNAs in cancer and Small cell lung cancer. The drugs Prednisone and Ciprofloxacin have been mentioned in the context of this disorder. Affiliated tissues include nervous system, brain and lung, and related phenotypes are neoplasm and renal/urinary system

Related Diseases for Nervous System Cancer

Diseases in the Nervous System Cancer family:

Central Nervous System Cancer

Diseases related to Nervous System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 546)
# Related Disease Score Top Affiliating Genes
1 central nervous system cancer 35.3 U2AF1 NF2 NF1 MIR9-1 MIR34A MIR21
2 autonomic nervous system neoplasm 35.2 U2AF1 MIR9-1 MIR34A MIR199A1 MIR196A1 MIR17
3 brain cancer 33.4 NF2 NF1 MIR9-1 MIR17 KDM4C H2AC18
4 peripheral nervous system neoplasm 32.8 U2AF1 NF2 NF1 MIR9-1 MIR34A MIR199A1
5 meningioma, familial 31.5 NF2 NF1 MIR34A H2AC18 CDKN2B
6 benign ependymoma 31.3 NF2 NF1 CDKN2B
7 glioblastoma multiforme 31.2 NF2 NF1 MIR34A MIR21 MIR196A1 GLIPR1
8 spinal meningioma 31.2 NF2 NF1
9 neuroblastoma 31.1 NPY NF1 MIR34A MIR21 MIR17 MIR125A
10 grade iii astrocytoma 31.1 MIR196A1 KDM4C H2AC18 CDKN2B
11 neurofibromatosis, type iv, of riccardi 31.1 NF2 NF1 CDKN2B-AS1
12 glioma 31.1 NF1 MIR34A MIR21 MIR17 GLIPR1 CDKN2B-AS1
13 plexiform schwannoma 31.1 NF2 NF1
14 thyroid gland papillary carcinoma 31.0 MIR9-1 MIR199A1 MIR17 MIR125A
15 medulloblastoma 31.0 NF1 MIR9-1 MIR34A MIR17 MIR125A MIR124-1
16 fibrillary astrocytoma 30.9 NF1 KDM4C H2AC18
17 skin melanoma 30.9 MIR199A1 H2AC18 CDKN2B CASP3
18 breast cancer 30.9 NF2 NF1 MIR9-1 MIR34A MIR21 MIR199A1
19 cellular schwannoma 30.9 NF2 NF1
20 leukemia, acute myeloid 30.9 U2AF1 NF1 MIR9-1 MIR34A MIR21 MIR199A1
21 b-cell lymphoma 30.8 MIR21 MIR17 CDKN2B CASP3 BCL2
22 leukemia, acute lymphoblastic 30.8 U2AF1 MIR9-1 MIR21 MIR196A1 MIR17 MIR125A
23 spinal cord disease 30.8 NF2 NF1 H2AC18
24 esophageal cancer 30.8 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1 MIR124-1
25 myelodysplastic syndrome 30.8 U2AF1 NF1 MIR34A CDKN2B CASP3 BCL2
26 renal cell carcinoma, nonpapillary 30.8 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1 MIR17
27 epithelioid neurofibroma 30.8 NF2 NF1
28 lymphoma, non-hodgkin, familial 30.7 U2AF1 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
29 pancreatic cancer 30.7 MIR34A MIR21 MIR199A1 MIR196A1 MIR17 MIR125A
30 leukemia, chronic lymphocytic 30.7 U2AF1 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
31 lung cancer 30.7 U2AF1 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
32 wilms tumor 1 30.6 U2AF1 MIR125A H2AC18 CASP3 BCL2
33 small cell cancer of the lung 30.4 U2AF1 MIR21 BCL2
34 inherited nervous system cancer-predisposing syndrome 12.3
35 olfactory neural tumor 12.3
36 glioma susceptibility 1 11.7
37 mismatch repair cancer syndrome 11.6
38 rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome 11.6
39 ewing sarcoma 11.4
40 rare nervous system tumor 11.3
41 glioma susceptibility 2 11.1
42 glioma susceptibility 3 11.1
43 glioma susceptibility 9 11.1
44 central nervous system hematologic cancer 11.1
45 neurofibromatosis, type ii 11.1
46 ectomesenchymoma 11.1
47 schwannomatosis 1 11.1
48 melanoma-astrocytoma syndrome 11.1
49 central nervous system primitive neuroectodermal neoplasm 11.1
50 central nervous system sarcoma 11.1

Graphical network of the top 20 diseases related to Nervous System Cancer:

Diseases related to Nervous System Cancer

Symptoms & Phenotypes for Nervous System Cancer

MGI Mouse Phenotypes related to Nervous System Cancer:

# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.5 APC BCL2 CDKN2B GLIPR1 KDM4C NF1
2 renal/urinary system MP:0005367 9.17 APC BCL2 CASP3 CDKN2B NF1 NF2

Drugs & Therapeutics for Nervous System Cancer

Drugs for Nervous System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 426)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
3 Orange Approved Phase 3
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
Ondansetron Approved Phase 3 99614-02-5 4595
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
Trioxsalen Approved Phase 3 3902-71-4 5585
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
Thioguanine Approved Phase 3 154-42-7 2723601
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
Ofloxacin Approved Phase 3 82419-36-1 4583
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
Cisatracurium Approved Phase 3 96946-41-7
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
24 Mitolactol Investigational Phase 3 10318-26-0
25 Antitubercular Agents Phase 3
26 Amoxicillin-Potassium Clavulanate Combination Phase 3
27 beta-Lactamase Inhibitors Phase 3
28 BB 1101 Phase 3
29 Analgesics Phase 3
30 Central Nervous System Depressants Phase 3
31 Autonomic Agents Phase 3
32 Emetics Phase 3
33 Antiemetics Phase 3
34 Hematoporphyrin Derivative Phase 3
35 Ether Phase 3
36 Hematoporphyrins Phase 3
37 Dihematoporphyrin Ether Phase 3
38 Anesthetics, Inhalation Phase 3
39 Cytochrome P-450 Enzyme Inhibitors Phase 3
40 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
41 Renal Agents Phase 3
42 Anti-Infective Agents, Urinary Phase 3
43 Narcotics Phase 3
44 Analgesics, Opioid Phase 3
45 Hormones Phase 3
46 calcium channel blockers Phase 3
47 Antihypertensive Agents Phase 3
48 Tocolytic Agents Phase 3
49 Anti-Arrhythmia Agents Phase 3
50 Vasoconstrictor Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 613)
# Name Status NCT ID Phase Drugs
1 A Randomized, Open Label, Two-way Crossover, Single Dose Bioequivalence Study Comparing Dralitem® Capsules to the Reference Drug Temodal® Capsules in Patients With Primary Tumors of the Central Nervous System Under Fasting Conditions Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
2 A Prospective Randomised Controlled Trial Of Hyperfractionated Versus Conventionally Fractionated Radiotherapy In Standard Risk Medulloblastoma Unknown status NCT00053872 Phase 3 cisplatin;lomustine;vincristine sulfate
3 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
4 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
5 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
6 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
7 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
8 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
11 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
12 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
13 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
14 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
15 Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study Completed NCT00006353 Phase 3 temozolomide
16 Trial of Chemotherapy Utilizing Carboplatin, Vincristine, Cyclophosphamide and Etoposide for the Treatment of Central Nervous System Primitive Neurectodermal Tumors of Childhood Completed NCT00003859 Phase 3 carboplatin;cyclophosphamide;etoposide;vincristine sulfate
17 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
18 A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
19 Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
20 Phase III Prospective Randomized Study of Craniospinal RT Followed by One of Two Adjuvant Chemotherapy Regimens (CCNU, CDDP, VCR OR CPM, CDDP, VCR) for Newly-Diagnosed Average Risk MedulloblastomaMEDULLOBLASTOMA Completed NCT00002875 Phase 3 cisplatin;cyclophosphamide;lomustine;mesna;vincristine sulfate
22 Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
23 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
24 A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children Completed NCT00716976 Phase 3 sodium thiosulfate
25 SIOP Intracranial Germ Cell Tumours Protocol Completed NCT00293358 Phase 3 carboplatin;cisplatin;etoposide phosphate;ifosfamide
26 A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients Completed NCT00482677 Phase 3 temozolomide
27 Radiotherapy Alone Versus Chemotherapy Followed By Response-Based Radiotherapy For Newly Diagnosed Primary CNS Germinoma Completed NCT00085098 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
28 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
29 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
30 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
31 Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
32 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
33 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
34 A Randomized, Blinded Study of Fluorescence Detection of Pediatric Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System Recruiting NCT03579602 Phase 2, Phase 3 tozuleristide
35 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
36 Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas Active, not recruiting NCT00978458 Phase 3 temozolomide
37 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Active, not recruiting NCT00085202 Phase 3 cisplatin;cyclophosphamide;vincristine
38 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial. Active, not recruiting NCT00626990 Phase 3 temozolomide
39 The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal Not yet recruiting NCT03558516 Phase 3 Magnesium group;Normal saline group
40 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
41 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
42 Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
43 The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric CNS Tumors Unknown status NCT02050243 Phase 1, Phase 2 5ALA
44 Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00562419 Phase 2 CT-322;irinotecan hydrochloride
45 Phase II Study Trial Of Tarceva In Patients With Recurrent/Progressive Glioblastoma Multiforme Unknown status NCT00054496 Phase 2 erlotinib hydrochloride
46 A Phase I and Enrichment Study of Low-dose Metronomic Topotecan and Pazopanib in Pediatric Patients With Recurrent or Refractory Solid Tumours Including CNS Tumours Unknown status NCT02303028 Phase 1, Phase 2 Topotecan and Pazopanib
47 Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
48 Treatment of Children With Newly Diagnosed Diffuse Pontine Gliomas Using Conventional Radiotherapy and High Dose Tamoxifen Unknown status NCT00024336 Phase 2 tamoxifen citrate
49 A Phase I/II Trial of Conformal Radiotherapy and Hyperbaric Oxygen for Patients With Newly Diagnosed Glioblastoma Unknown status NCT00006460 Phase 1, Phase 2 hyperbaric oxygen
50 Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma Unknown status NCT00006119 Phase 2 hydroxyurea

Search NIH Clinical Center for Nervous System Cancer

Cochrane evidence based reviews: neoplasms, nerve tissue

Genetic Tests for Nervous System Cancer

Genetic tests related to Nervous System Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of the Nervous System 29

Anatomical Context for Nervous System Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Nervous System Cancer:

Nervous System

MalaCards organs/tissues related to Nervous System Cancer:

Brain, Lung, Thyroid, Breast, T Cells, Prostate, Pituitary

Publications for Nervous System Cancer

Articles related to Nervous System Cancer:

(show top 50) (show all 194)
# Title Authors PMID Year
High incidence of brain and other nervous system cancer identified in two mining counties, 2001-2015. 61
32007285 2020
Case-control study of brain and other central nervous system cancer among workers at semiconductor and storage device manufacturing facilities. 61
32019845 2020
Nonpharmacological interventions for cancer-related cognitive impairment in adult cancer patients: A network meta-analysis. 61
32004776 2020
Glioma stages prediction based on machine learning algorithm combined with protein-protein interaction networks. 61
31150762 2020
Recent advances on anti-tumor agents-loaded polymeric and lipid based nano-carriers for the treatment of brain cancer. 61
31951159 2020
Bioactive naphthoquinone and anthrone derivatives from endophytic Micromonospora sp. NEAU-gq13. 61
30585513 2019
How to assess and manage cognitive impairment induced by treatments of non-central nervous system cancer. 61
31553925 2019
Spinal Clear Cell Meningiomas: Clinical Features and Factors Predicting Recurrence. 61
31765868 2019
PD-L1/PD-1 Axis in Glioblastoma Multiforme. 61
31661771 2019
Donors with central nervous system cancer: Proceed with vigilance. 61
31596741 2019
Therapeutic potential of natural products in glioblastoma treatment: targeting key glioblastoma signaling pathways and epigenetic alterations. 61
31630356 2019
Bimodular Antiparallel G-Quadruplex Nanoconstruct with Antiproliferative Activity. 61
31597343 2019
Neuropsychological disorders in non-central nervous system cancer: a review of objective cognitive impairment, depression, and related rehabilitation options. 61
31049790 2019
Age, cancer site and gender associations with symptoms and problems in specialised palliative care: a large, nationwide, register-based study. 61
31563863 2019
Genetic epidemiology of colorectal cancer and associated cancers. 61
31424514 2019
The Association between Mortality-to-Incidence Ratios and Health Expenditures in Brain and Nervous System Cancers. 61
31370357 2019
Evidence for increased surveillance of executive functioning in adolescent and young adult survivors of childhood cancer. 61
30395335 2019
Genetic variation of matrix metalloproteinase enzyme in HIV-associated neurocognitive disorder. 61
30825593 2019
Mortality among autoworkers manufacturing electronics in Huntsville, Alabama. 61
30569473 2019
Retrospective Exposure Assessment for Semiconductor and Storage Device Manufacturing Facilities. 61
30946698 2019
Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma. 61
31013819 2019
Radiological imaging and orthodontic treatment in the case of growing patients after oncological treatment: Case reports. 61
31099502 2019
Fluorodeoxyglucose Detected Changes in Brain Metabolism After Chemotherapy in Pediatric Non-Hodgkin Lymphoma. 61
30630683 2019
Familial Associations of Colon and Rectal Cancers With Other Cancers. 61
30640834 2019
Racial and ethnic differences in survival of pediatric patients with brain and central nervous system cancer in the United States. 61
30350913 2019
miR-26b Mimic Inhibits Glioma Proliferation In Vitro and In Vivo Suppressing COX-2 Expression. 61
28800785 2019
Functional Polymorphisms in BARD1 Association with Neuroblastoma in a regional Han Chinese Population. 61
31258718 2019
Association Between Cancer Incidence and Mortality in Web-Based Data in China: Infodemiology Study. 61
30694203 2019
Risk of Radiation-Induced Cancer From Computed Tomography Angiography Use in Imaging Surveillance for Unruptured Cerebral Aneurysms. 61
30580703 2018
Cancer and dementia: Two sides of the same coin? 61
30112764 2018
Ovarian response after random-start controlled ovarian stimulation to cryopreserve oocytes in cancer patients. 61
30264947 2018
Exosomes impact survival to radiation exposure in cell line models of nervous system cancer. 61
30546829 2018
Hyaluronic-Acid Based Hydrogels for 3-Dimensional Culture of Patient-Derived Glioblastoma Cells. 61
30199037 2018
Differential somatostatin, CXCR4 chemokine and endothelin A receptor expression in WHO grade I-IV astrocytic brain tumors. 61
29696364 2018
Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: Targeting the source. 61
29461625 2018
Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. 61
29511029 2018
Cardiovascular disease incidence in adolescent and young adult cancer survivors: a retrospective cohort study. 61
29427203 2018
Integrated analysis of microarray data to identify the genes critical for the rupture of intracranial aneurysm. 61
29552131 2018
Outcomes of Organ Transplantation from Donors with a Cancer History. 61
29455213 2018
Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer. 61
30140655 2018
Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review. 61
29374660 2018
Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors. 61
28426850 2017
Benefits of marriage on relative and conditional relative cancer survival differ between males and females in the USA. 61
28770444 2017
Brain cortical structural differences between non-central nervous system cancer patients treated with and without chemotherapy compared to non-cancer controls: a cross-sectional pilot MRI study using clinically-indicated scans. 61
30034079 2017
Improving Functional Mobility in Children and Adolescents Undergoing Treatment for Non-Central Nervous System Cancers: A Systematic Review. 61
28942910 2017
Photodithazine photodynamic effect on viability of 9L/lacZ gliosarcoma cell line. 61
28503718 2017
The Complex Diagnostic Challenge in Children With Non-Central Nervous System Cancer and Cerebellar Mutism. 61
28497710 2017
Biomarkers and Immunotherapeutic Targets in Glioblastoma. 61
28300714 2017
Integrated analysis of genome-wide DNA methylation and gene expression data provide a regulatory network in intrauterine growth restriction. 61
28465243 2017
Estimating the Proportion of Childhood Cancer Cases and Costs Attributable to the Environment in California. 61
28323471 2017

Variations for Nervous System Cancer

Expression for Nervous System Cancer

Search GEO for disease gene expression data for Nervous System Cancer.

Pathways for Nervous System Cancer

Pathways related to Nervous System Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.81 MIR9-1 MIR34A MIR21 MIR199A1 MIR17 MIR125A
2 11.3 CDKN2B CASP3 BCL2
3 10.79 CDKN2B CASP3 BCL2

GO Terms for Nervous System Cancer

Biological processes related to Nervous System Cancer according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.92 MIR34A MIR21 MIR125A KDM4C CDKN2B-AS1
2 negative regulation of gene expression GO:0010629 9.77 MIR21 MIR17 MIR125A MIR124-1 CDKN2B-AS1
3 cellular response to hypoxia GO:0071456 9.76 MIR34A MIR17 MIR124-1 BCL2
4 regulation of protein stability GO:0031647 9.72 NF2 CASP3 BCL2
5 negative regulation of angiogenesis GO:0016525 9.71 NF1 MIR34A MIR21 MIR125A
6 negative regulation of cell proliferation GO:0008285 9.7 NF2 NF1 MIR9-1 MIR21 CDKN2B BCL2
7 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.67 MIR21 CDKN2B BCL2
8 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.61 CDKN2B CASP3 APC
9 negative regulation of osteoblast proliferation GO:0033689 9.58 MIR9-1 BCL2
10 positive regulation of connective tissue replacement GO:1905205 9.58 MIR34A MIR199A1
11 regulation of cell-matrix adhesion GO:0001952 9.57 NF1 BCL2
12 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.56 MIR199A1 MIR17
13 miRNA mediated inhibition of translation GO:0035278 9.56 MIR9-1 MIR21 MIR17 MIR124-1
14 positive regulation of metalloendopeptidase activity GO:1904685 9.54 MIR21 MIR17
15 positive regulation of vascular smooth muscle cell differentiation GO:1905065 9.51 MIR21 MIR124-1
16 negative regulation of MAPK cascade GO:0043409 9.5 NF2 NF1 MIR21
17 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.48 MIR21 MIR17
18 negative regulation of cell migration GO:0030336 9.43 NF2 NF1 MIR9-1 MIR34A MIR21 BCL2
19 gene silencing by miRNA GO:0035195 9.23 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1 MIR17

Molecular functions related to Nervous System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1 MIR17
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.96 CDKN2B CASP3

Sources for Nervous System Cancer

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....